169 related articles for article (PubMed ID: 25182454)
1. Multicenter dose-finding and efficacy and safety outcomes in neonates and children treated with dalteparin for acute venous thromboembolism.
O'Brien SH; Kulkarni R; Wallace A; Hamblin F; Burr S; Goldenberg NA
J Thromb Haemost; 2014 Nov; 12(11):1822-5. PubMed ID: 25182454
[TBL] [Abstract][Full Text] [Related]
2. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study.
Francis CW; Kessler CM; Goldhaber SZ; Kovacs MJ; Monreal M; Huisman MV; Bergqvist D; Turpie AG; Ortel TL; Spyropoulos AC; Pabinger I; Kakkar AK
J Thromb Haemost; 2015 Jun; 13(6):1028-35. PubMed ID: 25827941
[TBL] [Abstract][Full Text] [Related]
3. Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
McBane Ii R; Loprinzi CL; Ashrani A; Perez-Botero J; Leon Ferre RA; Henkin S; Lenz CJ; Le-Rademacher JG; Wysokinski WE
Thromb Haemost; 2017 Oct; 117(10):1952-1961. PubMed ID: 28837207
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetic Analysis of Dalteparin in Pediatric Patients With Venous Thromboembolism.
Damle B; Jen F; Sherman N; Jani D; Sweeney K
J Clin Pharmacol; 2021 Feb; 61(2):172-180. PubMed ID: 32827160
[TBL] [Abstract][Full Text] [Related]
5. Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients.
Droege ME; Mueller EW; Besl KM; Lemmink JA; Kramer EA; Athota KP; Droege CA; Ernst NE; Keegan SP; Lutomski DM; Hanseman DJ; Robinson BR
J Trauma Acute Care Surg; 2014 Feb; 76(2):450-6. PubMed ID: 24458050
[TBL] [Abstract][Full Text] [Related]
6. Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study.
Di Nisio M; van Es N; Carrier M; Wang TF; Garcia D; Segers A; Weitz J; Buller H; Raskob G
J Thromb Haemost; 2019 Nov; 17(11):1866-1874. PubMed ID: 31271705
[TBL] [Abstract][Full Text] [Related]
7. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI
Thromb Haemost; 2010 Sep; 104(3):642-9. PubMed ID: 20589317
[TBL] [Abstract][Full Text] [Related]
8. A phase 2 pharmacodynamic dose-finding, safety, and efficacy study of dalteparin for pediatric venous thromboembolism treatment in children with and without cancer.
Hartman LR; Nurmeev I; Svirin P; Wolter KD; Yan JL; Jani D; Goldenberg NA; Sherman N
Pediatr Blood Cancer; 2022 Aug; 69(8):e29764. PubMed ID: 35678616
[TBL] [Abstract][Full Text] [Related]
9. Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial.
Goldenberg NA; Kittelson JM; Abshire TC; Bonaca M; Casella JF; Dale RA; Halperin JL; Hamblin F; Kessler CM; Manco-Johnson MJ; Sidonio RF; Spyropoulos AC; Steg PG; Turpie AGG; Schulman S;
JAMA; 2022 Jan; 327(2):129-137. PubMed ID: 35015038
[TBL] [Abstract][Full Text] [Related]
10. Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.
Kraaijpoel N; Di Nisio M; Mulder FI; van Es N; Beyer-Westendorf J; Carrier M; Garcia D; Grosso M; Kakkar AK; Mercuri MF; Middeldorp S; Hernandez CR; Santamaria A; Schwocho L; Segers A; Verhamme P; Wang TF; Weitz JI; Zhang G; Zwicker JI; Büller HR; Raskob GE
Thromb Haemost; 2018 Aug; 118(8):1439-1449. PubMed ID: 30060256
[TBL] [Abstract][Full Text] [Related]
11. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
Agnelli G; Becattini C; Meyer G; Muñoz A; Huisman MV; Connors JM; Cohen A; Bauersachs R; Brenner B; Torbicki A; Sueiro MR; Lambert C; Gussoni G; Campanini M; Fontanella A; Vescovo G; Verso M;
N Engl J Med; 2020 Apr; 382(17):1599-1607. PubMed ID: 32223112
[TBL] [Abstract][Full Text] [Related]
12. Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women.
Bauersachs RM; Dudenhausen J; Faridi A; Fischer T; Fung S; Geisen U; Harenberg J; Herchenhan E; Keller F; Kemkes-Matthes B; Schinzel H; Spannagl M; Thaler CJ;
Thromb Haemost; 2007 Dec; 98(6):1237-45. PubMed ID: 18064320
[TBL] [Abstract][Full Text] [Related]
13. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).
Young AM; Marshall A; Thirlwall J; Chapman O; Lokare A; Hill C; Hale D; Dunn JA; Lyman GH; Hutchinson C; MacCallum P; Kakkar A; Hobbs FDR; Petrou S; Dale J; Poole CJ; Maraveyas A; Levine M
J Clin Oncol; 2018 Jul; 36(20):2017-2023. PubMed ID: 29746227
[TBL] [Abstract][Full Text] [Related]
14. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
Raskob GE; van Es N; Verhamme P; Carrier M; Di Nisio M; Garcia D; Grosso MA; Kakkar AK; Kovacs MJ; Mercuri MF; Meyer G; Segers A; Shi M; Wang TF; Yeo E; Zhang G; Zwicker JI; Weitz JI; Büller HR;
N Engl J Med; 2018 Feb; 378(7):615-624. PubMed ID: 29231094
[TBL] [Abstract][Full Text] [Related]
15. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies.
Monagle P; Lensing AWA; Thelen K; Martinelli I; Male C; Santamaría A; Samochatova E; Kumar R; Holzhauer S; Saracco P; Simioni P; Robertson J; Grangl G; Halton J; Connor P; Young G; Molinari AC; Nowak-Göttl U; Kenet G; Kapsa S; Willmann S; Pap AF; Becka M; Twomey T; Beyer-Westendorf J; Prins MH; Kubitza D;
Lancet Haematol; 2019 Oct; 6(10):e500-e509. PubMed ID: 31420317
[TBL] [Abstract][Full Text] [Related]
16. A retrospective analysis of outcomes of dalteparin use in pediatric patients: a single institution experience.
Warad D; Rao AN; Mullikin T; Graner K; Shaughnessy WJ; Pruthi RK; Rodriguez V
Thromb Res; 2015 Aug; 136(2):229-33. PubMed ID: 26026634
[TBL] [Abstract][Full Text] [Related]
17. FDA approval summary: Dalteparin for the treatment of symptomatic venous thromboembolism in pediatric patients.
Merino M; Richardson N; Reaman G; Ande A; Zvada S; Liu C; Hariharan S; De Claro RA; Farrell A; Pazdur R
Pediatr Blood Cancer; 2020 Dec; 67(12):e28688. PubMed ID: 32896942
[TBL] [Abstract][Full Text] [Related]
18. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Lee AY; Levine MN; Baker RI; Bowden C; Kakkar AK; Prins M; Rickles FR; Julian JA; Haley S; Kovacs MJ; Gent M;
N Engl J Med; 2003 Jul; 349(2):146-53. PubMed ID: 12853587
[TBL] [Abstract][Full Text] [Related]
19. A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment.
Woodruff S; Feugère G; Abreu P; Heissler J; Ruiz MT; Jen F
J Thromb Thrombolysis; 2016 Nov; 42(4):494-504. PubMed ID: 27344439
[TBL] [Abstract][Full Text] [Related]
20. Tinzaparin versus dalteparin for periprocedure prophylaxis of thromboembolic events in hemodialysis patients: a randomized trial.
Rodger MA; Ramsay T; MacKinnon M; Westphal M; Wells PS; McCormick B; Knoll G
Am J Kidney Dis; 2012 Sep; 60(3):427-34. PubMed ID: 22480794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
